These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1008913)

  • 41. Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism.
    Herrera E; Lasunción MA; Castro M; Gómez-Coronado D; Martín A; Quack G
    Biochim Biophys Acta; 1988 Nov; 963(1):42-52. PubMed ID: 3179329
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyperlipoproteinemia. 3. Drug therapy.
    LaRosa JC
    Postgrad Med; 1972 Aug; 52(2):128-32. PubMed ID: 5047023
    [No Abstract]   [Full Text] [Related]  

  • 43. [The when and how of therapy for hyperlipoproteinemia].
    Mordasini R
    Schweiz Med Wochenschr; 1978 Jan; 108(4):113-9. PubMed ID: 203028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
    Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
    MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative study on the in vivo and in vitro antilipolytic effects of etofibrate, nicotinic acid and clofibrate in the rat.
    Bocos C; Herrera E
    Environ Toxicol Pharmacol; 1996 Dec; 2(4):351-7. PubMed ID: 21781742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
    Jastrzebska M; Torbus-Lisiecka B; Pieczul-Mróz J; Chelstowski K; Kopciewicz J; Naruszewicz M
    Int J Clin Pharmacol Res; 1999; 19(1):19-25. PubMed ID: 10450539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical and experimental studies on fibrinolysis activation].
    Bielawiec M
    Rocz Akad Med Im Juliana Marchlewskiego Bialymst Suppl; 1967; 15():1-92. PubMed ID: 4953138
    [No Abstract]   [Full Text] [Related]  

  • 49. [Influence of etofibrate on plasmaviscosity in hyperlipoproteinemias (author's transl)].
    Pfeiffer M; Tilsner V
    Med Klin; 1978 Jan; 73(2):60-2. PubMed ID: 622057
    [No Abstract]   [Full Text] [Related]  

  • 50. [Preliminary study of the tolerance of 3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate (I. 612) and on its effects on plasma lipid pattern, hemostasis and clotting-fibrinolysis balance].
    Buzzelli G; Doni A; Lippi G; Resina A
    Clin Ter; 1979 May; 89(3):251-66. PubMed ID: 466976
    [No Abstract]   [Full Text] [Related]  

  • 51. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
    Schwartzkopff W; Schilling A; Calder D
    Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415
    [No Abstract]   [Full Text] [Related]  

  • 52. Dietary and drug treatment of primary hyperlipoproteinemia.
    Ann Intern Med; 1972 Aug; 77(2):267-94. PubMed ID: 4345081
    [No Abstract]   [Full Text] [Related]  

  • 53. Effects of etofibrate on platelet function: in vitro studies in human plasma.
    Ortega MP; Sunkel C; Armijo M; Priego JG
    Thromb Res; 1980 Aug; 19(3):409-16. PubMed ID: 7001672
    [No Abstract]   [Full Text] [Related]  

  • 54. [Familial hyperlipoproteinemia type III].
    Patsch JR; Patsch W; Sailer S; Braunsteiner H
    Dtsch Med Wochenschr; 1976 Oct; 101(44):1612-9. PubMed ID: 185039
    [No Abstract]   [Full Text] [Related]  

  • 55. [Lipid-lowering effect of a combination of clofibrate and DL-alpha-tocopherol nicotinate in unselected hyperlipemic patients].
    Gniwotta E; Herter B
    ZFA (Stuttgart); 1977 Apr; 53(10):565-8. PubMed ID: 324162
    [No Abstract]   [Full Text] [Related]  

  • 56. Dose-response effect of single and combined clofibrate (Atromidin) and niceritrol (Perycit) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia.
    Olsson AG; Orö L; Rössner S
    Atherosclerosis; 1975; 22(1):91-101. PubMed ID: 1098680
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hyperlipoproteinemia. Some basic concepts on diagnosis and management.
    Levy RI
    JAMA; 1973 Nov; 226(6):648-9. PubMed ID: 4356846
    [No Abstract]   [Full Text] [Related]  

  • 58. The treatment of hyperlipidemia.
    Lees RS; Wilson DE
    N Engl J Med; 1971 Jan; 284(4):186-95. PubMed ID: 4923684
    [No Abstract]   [Full Text] [Related]  

  • 59. [The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
    Mertz DP; Loewer H; Suermann I
    Med Klin; 1979 Dec; 74(51-52):1953-6. PubMed ID: 542179
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelet kinetic studies in patients with hyperlipoproteinemia: effects of clofibrate therapy.
    Harker LA; Hazzard W
    Circulation; 1979 Sep; 60(3):492-6. PubMed ID: 455611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.